Dataset Information

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

ABSTRACT: This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy. RT-CAMSS is a monitoring support system that provides patients with evidence-based information and side-effect management and coping skills, emotional support and validation, and proactive care via text messages and questionnaires as they undergo chemotherapy.

DISEASE(S): Clinical Stage I Esophageal Adenocarcinoma Ajcc V8,Adenocarcinoma,Stage 0 Colorectal Cancer Ajcc V8,Clinical Stage Ivb Gastric Cancer Ajcc V8,Carcinoma,Pathologic Stage Ia Gastric Cancer Ajcc V8,Pathologic Stage Iva Esophageal Squamous Cell Carcinoma Ajcc V8,Pathologic Stage Iib Gastric Cancer Ajcc V8,Pathologic Stage Iii Gastric Cancer Ajcc V8,Stage Iiic Colorectal Cancer Ajcc V8,Pathologic Stage Iib Esophageal Squamous Cell Carcinoma Ajcc V8,Carcinoma In Situ,Pathologic Stage Iib Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Ivb Esophageal Squamous Cell Carcinoma Ajcc V8,Pathologic Stage Iv Esophageal Squamous Cell Carcinoma Ajcc V8,Esophageal Neoplasms,Pathologic Stage Ivb Esophageal Adenocarcinoma Ajcc V8,Stage Iia Colorectal Cancer Ajcc V8,Pathologic Stage I Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Ia Esophageal Adenocarcinoma Ajcc V8,Stage I Colorectal Cancer Ajcc V8,Clinical Stage Iii Gastric Cancer Ajcc V8,Stage Ia Pancreatic Cancer Ajcc V8,Pathologic Stage 0 Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage Iii Esophageal Squamous Cell Carcinoma Ajcc V8,Stomach Neoplasms,Clinical Stage Iia Gastric Cancer Ajcc V8,Pathologic Stage Iia Esophageal Squamous Cell Carcinoma Ajcc V8,Esophageal Squamous Cell Carcinoma,Stage Iiib Colorectal Cancer Ajcc V8,Clinical Stage Iv Gastric Cancer Ajcc V8,Clinical Stage Ii Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage I Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage Iv Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Ia Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Iiia Colorectal Cancer Ajcc V8,Stage I Pancreatic Cancer Ajcc V8,Carcinoma, Squamous Cell,Pathologic Stage Ii Esophageal Adenocarcinoma Ajcc V8,Clinical Stage Ivb Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Iii Esophageal Squamous Cell Carcinoma Ajcc V8,Pathologic Stage 0 Gastric Cancer Ajcc V8,Clinical Stage Iva Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Iva Colorectal Cancer Ajcc V8,Stage Iib Pancreatic Cancer Ajcc V8,Pathologic Stage Ii Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage Ii Gastric Cancer Ajcc V8,Pathologic Stage Iii Esophageal Adenocarcinoma Ajcc V8,Clinical Stage Iva Esophageal Adenocarcinoma Ajcc V8,Clinical Stage 0 Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Ivb Colorectal Cancer Ajcc V8,Clinical Stage 0 Gastric Cancer Ajcc V8,Pathologic Stage Iiia Esophageal Adenocarcinoma Ajcc V8,Clinical Stage 0 Esophageal Adenocarcinoma Ajcc V8,Stage Iii Pancreatic Cancer Ajcc V8,Pathologic Stage Iiib Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Iia Pancreatic Cancer Ajcc V8,Pathologic Stage 0 Esophageal Adenocarcinoma Ajcc V8,Colorectal Neoplasms,Pathologic Stage I Gastric Cancer Ajcc V8,Clinical Stage Iia Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Iiia Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Iv Pancreatic Cancer Ajcc V8,Pathologic Stage Iiia Gastric Cancer Ajcc V8,Pancreatic Neoplasms,Clinical Stage Iva Gastric Cancer Ajcc V8,Stage Ivc Colorectal Cancer Ajcc V8,Pathologic Stage Iiic Gastric Cancer Ajcc V8,Pathologic Stage Ic Esophageal Adenocarcinoma Ajcc V8,Stage Iv Colorectal Cancer Ajcc V8,Pathologic Stage Ib Gastric Cancer Ajcc V8,Stage Ib Pancreatic Cancer Ajcc V8,Pathologic Stage Ib Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage Iii Esophageal Adenocarcinoma Ajcc V8,Stage Iic Colorectal Cancer Ajcc V8,Pathologic Stage Iia Gastric Cancer Ajcc V8,Pathologic Stage Iva Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Iv Gastric Cancer Ajcc V8,Clinical Stage Iv Esophageal Squamous Cell Carcinoma Ajcc V8,Clinical Stage I Gastric Cancer Ajcc V8,Stage Ii Pancreatic Cancer Ajcc V8,Clinical Stage Ivb Esophageal Squamous Cell Carcinoma Ajcc V8,Stage Ii Colorectal Cancer Ajcc V8,Pathologic Stage Ii Gastric Cancer Ajcc V8,Pathologic Stage Iia Esophageal Adenocarcinoma Ajcc V8,Clinical Stage Iib Gastric Cancer Ajcc V8,Stage Iii Colorectal Cancer Ajcc V8,Stage Iib Colorectal Cancer Ajcc V8,Pathologic Stage Iv Esophageal Adenocarcinoma Ajcc V8,Clinical Stage Ii Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage I Esophageal Squamous Cell Carcinoma Ajcc V8,Pathologic Stage Iiib Gastric Cancer Ajcc V8,Stage 0 Pancreatic Cancer Ajcc V8,Pathologic Stage Ib Esophageal Adenocarcinoma Ajcc V8,Pathologic Stage Iiib Esophageal Adenocarcinoma Ajcc V8

PROVIDER: 2343939 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Individual stress coping style has profound effects on how animals respond to environmental change, and individuals within a population strikingly differ in how gene expression shifts in response to challenge. This study used a wild type Zebrafish (Danio rerio) population to: 1) identify and screen for individual coping style using a screening protocol for risk taking in groups and 2) do global transcriptomics of brains from proactive, reactive or randomly chosen individuals (n=10/group) under control conditions. Results show that within our population proactive and reactive individual coping styles can be accurately identified and may represent 10-30% of individuals within the population. Microarray data analyses identify fundamental differences between the three different groups where variance in gene expression values are reduced by using coping style as an explanatory variable. Furthermore, significant differences in mRNAs and related biological processes suggest that even under identical environmental conditions the molecular mechanisms that underpin physiological processes are very different between proactive and reactive individuals within a population. Experimental tank was an 18 litre glass aquarium (dimensions (LxWxH): 40 X 25 X 20cm) lined on three sides with white paper; the front wall was not covered to allow the observer to record the behaviour and divided at 1/3 of his length with a black PVC screen with a 3cm diameter hole in the middle. All the tank surfaces around this third area of the tank were covered with dark paper and closed on the upper part with a removable lid to provide a shelter for the animals. The hole was covered with the same PVC plastic material and removed once the screening started to allow the fish enter the novel environment. Food was not supplied the day before to ensure that during the test the fish were hungry and they had to make the decision to leave a safe area in order to forage. Boldness was measured as the time taken by individual fish to leave a group from a safe, darkened area. It hence represents the willingness of a fish to explore a new, potentially dangerous environment, or boldness. Tests were conducted with groups of 9 randomly-selected fish from stocking tanks. Fish were familiar to each other in the sense that they were previously held in the same stocking tank. Test started with a 10 min. habituation period in the sheltered area with the hole closed with a PVC screen and the top of the sheltered area of the tank also covered to provide a complete quiet place. Then the lid covering the hole was gently removed. Either the first 3 fish to exit the shelter or fish with latency times inferior to 10 minutes were considered bold fish and were removed gently with a fish net from the test tank and placed apart in another tank. Latency times of emergency from the sheltered area were recorded individually. Next 3 animals to emerge before 15 minutes were considered intermediate and also removed gently. At the end of this last 15 minutes, animals that still remained inside the sheltered area were considered shy. Intermediates were discarded and fish selected for different coping strategies where placed in different tanks for posterior molecular analysis. Selected animals were killed by an overdose of MS-22 and the brains were sampled. Individual tissue samples were homogenized into 0.3 ml of Tri-Reagent and stored at -80C for further molecular analysis.

Dataset Information

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure